Monitoring of Lipids, Enzymes, and Creatine Kinase in Patients on Lipid-Lowering Drug Therapy
Open accessThe DOI matches its Crossref record; the references it cites are not checked yet.
Abstract
A number of plasma lipid parameters have been used to estimate cardiovascular risk and to be targets for treatment to reduce risk. Most risk algorithms are based on total cholesterol (T-C) or low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C), and most intervention trials have targeted the LDL-C levels. Emerging measures, which in some cases may be better for risk calculation and as alternative treatment targets, are apolipoprotein B and non-HDL-C. Other lipid measures that may contribute in risk analysis are triglycerides (TG), lipoprotein(a), and lipoprotein-associated phospholipase A2. The primary treatment target in cardiovascular prevention is LDL-C, and potential alternative targets are apoB and non-HDL-C. In selected individuals at high cardiovascular (CV) risk, TG should be targeted, but HDL-C, Lp(a), and ratios such as LDL-C/HDL-C or apoB/apoAI are not recommended as treatment targets. Lipids should be monitored during titration to targets. Thereafter, lipids should be checked at least once a year or more frequently to improve treatment adherence if indicated. Monitoring of muscle and liver enzymes should be done before the start of treatment. In stable conditions during treatment, the focus should be on clinical symptoms that may alert muscle or liver complications. Routine measurement of CK or ALT is not necessary during treatment with statins.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Several studies have shown a considerable LDL-C-lowering effect of alternative dosing, such as every other day or twice a week, with atorvastatin or rosuvastatin [242].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [242]
In the citing paper
“Pravastatin does not undergo metabolism through the CYP system, but is metabolized by sulfation and conjugation.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [233]
In the citing paper
“A number of important drug interactions with statins have been described that may increase the risk of adverse effects.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [233]
In the citing paper
“All currently available statins, except pravastatin, rosuvastatin and pitavastatin, undergo major hepatic metabolism via the CYPs.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [233]
In the citing paper
“Moreover, although it has been suggested that the risk for diabetes increases with statin use by 9–13%, meta-analyses of large-scale RCTs suggest that incidence frequency is low (approximately one to two cases per 1,000 patients per year)708–710).”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [710]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
The citation lists are queued
They are fetched later and appear here then.
References 100 · Cited by 45
Metadata
- Authors
- Wiklund, O., Pirazzi, C., & Romeo, S.
- Affiliations
- Sahlgrenska University Hospital (SE)
- Corresponding author
- Wiklund, Olov
- Venue
- Current Cardiology Reports
- Published
- 2013-07-26
- Volume
- 15
- Issue
- 9
- Pages
- 397-397
- ISSN
- 1523-3782 (ISSN-L)
- 1534-3170
- PMC
- PMC3751280
- OpenAlex
- W2056320402
- Cited by
- 45
- References
- 100
- Citations by year
- 2026: 2 · 2024: 1 · 2023: 6 · 2022: 4 · 2021: 4 · 2020: 5 · 2019: 5 · 2018: 5 · 2017: 1 · 2016: 4 · 2015: 5 · 2014: 1 · 2013: 2
- FWCI
- 0.71
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Current Cardiology Reports (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- lipid-lowering therapy, lipid monitoring, cardiovascular risk, LDL cholesterol, apolipoprotein B, non-HDL cholesterol, triglycerides, lipoprotein(a), lipoprotein-associated phospholipase A2, statins, creatine kinase, liver enzymes, muscle enzymes, treatment goals, medication adherence
- MeSH terms
- Hypolipidemic Agents, Cardiovascular Diseases, Creatine Kinase, Clinical Enzyme Tests, Humans, Hyperlipidemias, Lipids, Drug Monitoring, Risk Assessment, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Monitoring of Lipids, Enzymes, and Creatine Kinase in Patients on Lipid-Lowering Drug Therapy. https://app.cochat.ai/papers/10.1007/s11886-013-0397-8
- The paper
- Wiklund, O., Pirazzi, C., & Romeo, S. (2013). Monitoring of Lipids, Enzymes, and Creatine Kinase in Patients on Lipid-Lowering Drug Therapy. Current Cardiology Reports. https://doi.org/10.1007/s11886-013-0397-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.